The central target of $104 is the arithmetic mean of roughly 30 verified analyst price targets reviewed for this analysis, with individual objectives ranging from about $83 to $121. At a latest verified price near $94, reaching $104 implies upside of roughly 11%, a modest move for a large-cap medtech name over a typical research horizon.
Medtronic (MDT) climbed from a closing price of $86.29 on September 30, 2026 to $96.54 on October 30, 2026, a gain of approximately +11.9% over 30 days. The move was driven primarily by the completed separation of its diabetes business, MiniMed Group, whose oversubscribed exchange offer retired roughly 55 million Medtronic shares.
Record investment cycle ahead: ITOCHU has earmarked roughly ¥1.5 trillion in growth investments for fiscal 2026 (ending March 2027), positioning it as a "gear shift" year aimed at creating the next generation of core earnings drivers. Earnings milestone in focus: Management is targeting a record ¥950 billion in consolidated net profit for fiscal 2026, with a stated ambition of reaching the ¥1 trillion threshold in fiscal 2027.
The $3.20 central target is not an analyst consensus; it is a valuation-based benchmark tied to the company's reported book value per share of roughly $3.22. With a latest verified close near $2.60, reaching $3.20 would require a gain of about 23%, a substantial move.
iTonic Holdings (ITOC) shares fell roughly 42% over the last 30 days, from about $4.48 on a split-adjusted basis to near $2.60 by late October. The decline followed a 1-for-16 reverse stock split that took effect in early October, a move that coincided with renewed selling pressure.
enVVeno Medical reported a third-quarter 2026 net loss of $4.4 million , or $6.29 per share , compared with a net loss of $4.5 million, or $7.89 per share, in the same period last year. Total operating expenses came in at $4.5 million , down from $4.9 million a year earlier, even as the company prepared to launch its pivotal clinical study.
Quantum-Si (QSI) shares climbed roughly 37% over the trailing 30 days, rising from a close near $1.07 in late September to about $1.47 in late October. The move was driven primarily by development milestones for its next-generation Proteus single-molecule protein sequencing platform.
Baird Medical (BDMD) shares have fallen roughly 81% over the past 30 days, sliding from about $0.75 to around $0.15. The decline extends a longer downtrend, with the stock down roughly 86% over the trailing three months.
LUNG shares climbed roughly 47% over the trailing 30 days, from about $1.91 to $2.81, with most of the move concentrated in the sessions following the company's third-quarter 2026 earnings release. The rally reflects Pulmonx's return to year-over-year revenue growth, its first global growth quarter since current leadership returned to the company.
OFIX dropped -11.62% during regular trading hours, falling from a previous close of $10.24 to $9.05. The selloff followed a spine-sector rout after direct competitor Alphatec Holdings missed Q3 revenue and cut its 2026 guidance, with its CEO citing softer thoracolumbar procedure volumes, fueling read-through concerns for peers like Orthofix.
Quanterix Corporation (QTRX) declined roughly 22.9% over the last 30 days, falling from a September 30 close of $3.71 to about $2.86. The drop extends a broader downtrend, with the stock down approximately 18.8% over the last quarter.
908 Devices (MASS) trades near $11.53 as of the latest session, down roughly 6.6% from its September 30 closing level of $12.34 over the trailing 30 days. The stock reached a 52-week high of about $13.35 in early October before consolidating, reflecting a pullback after a multi-month advance.
Commercial inflection underway: Second-quarter 2026 revenue rose 16% year over year, with U.S. sales up 33% and both the ReWalk Personal Exoskeleton and AlterG product lines growing double digits, signaling momentum in a partner-led go-to-market model. Capital-efficient expansion: The Ottobock Care pilot broadens ReWalk access across more than 50 U.S. clinics, positioning Lifeward to scale distribution without carrying the full cost burden alone.
The central LFWD stock price target discussed here is $20 , which is the arithmetic mean of two current analyst price targets of $10 and $30. At a recent verified price of roughly $5.91, reaching $20 would require a gain of about 238% , an exceptionally large move for a micro-cap.
Lifeward shares have declined roughly 11% over the past 30 days, from about $6.62 to near $5.87, extending a broader multi-month downtrend. The move reflects a thinly traded micro-cap contending with persistent liquidity and going-concern considerations rather than a single headline catalyst.
Butterfly Network (BFLY) shares fell roughly 24.8% over the last 30 days, from an adjusted closing price of $8.96 on September 30 to approximately $6.74 at the latest quote. The pullback followed a powerful multi-month advance in which the stock had roughly tripled over the trailing year, leaving it vulnerable to profit-taking.
IRMD fell -8.05% to $78.84 from its prior close of $85.74, gapping lower at the open during regular trading. The drop followed third-quarter results released before the bell: revenue of $24.2M beat estimates and non-GAAP EPS of $0.55 matched, but management cut full-year guidance (non-GAAP EPS to $2.07–$2.11, revenue to $91.6M–$93.1M) while gross margin held at 76% versus 78% a year ago on the 3870 pump ramp.
ATEC shares tumbled -32.81%, sliding from a prior close of $11.37 to $7.64, with the plunge beginning in premarket trading and persisting into the regular session. The drop followed Q3 2026 results: revenue of $221M missed the ~$225M consensus and adjusted EPS of $0.09 came in light, while management cut full-year revenue guidance to roughly $862M from $882M, citing weaker biologics attachment.
SYK dropped -6.91% to $290.21 from the prior close of $311.75 during today's regular session, extending an after-hours slide. The catalyst was a Q3 miss and lowered guidance: adjusted EPS of $3.52 (vs. $3.55) and revenue of $6.52B (vs. ~$6.62B), with 2026 organic sales growth cut to 6.5%–7.0% from 8.3%–9.3%.
Alphatec Holdings (ATEC) reported total revenue of $221 million for the third quarter of 2026, up 13% year over year but below the consensus estimate of roughly $225 million. Surgical revenue rose 14% to $202 million , supported by approximately 20% case volume growth and a 25% increase in net new surgeon users.